SNGX - Soligenix gets Japanese patent for synthetic hypericin production

Soligenix (SNGX) announces that the Japan Patent Office has allowed the patent application titled "Systems and Methods for Producing Synthetic Hypericin".The allowed claims are directed to unique, proprietary methods to produce a novel, highly purified form of synthetic hypericin, and are similar to those previously allowed in the United States.Synthetic hypericin is the active pharmaceutical ingredient in HyBryte (SGX301), the company's photodynamic therapy for first-line treatment of early stage CTCL, a class of non-Hodgkin's lymphoma.Shares up 1% premarket.

For further details see:

Soligenix gets Japanese patent for synthetic hypericin production